September 23, 2026 7:00 am EDT Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
August 6, 2026 7:00 am EDT Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026